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Abstract
Purpose
SMT C1100 is a utrophin modulator being evaluated as a treatment for Duchenne muscular
dystrophy (DMD). This study, the first in pediatric DMD patients, reports the safety, tolerabil-
ity and PK parameters of single and multiple doses of SMT C1100, as well as analyze
potential biomarkers of muscle damage.
Methods
This multicenter, Phase 1 study enrolled 12 patients, divided equally into three groups (A–
C). Group A were given 50 mg/kg on Days 1 and 11, and 50 mg/kg bid on Days 2 to 10.
Group B and C received 100 mg/kg on Days 1 and 11; Group B and Group C were given
100 mg/kg bid and 100 mg/kg tid, respectively, on Days 2 to 10. A safety review was per-
formed on all patients following the single dose and there was at least 2 weeks between
each dose escalation, for safety and PK review. Adverse events (AEs) were monitored
throughout the study.
Results
Most patients experienced mild AEs and there were no serious AEs. Two patients required
analgesia for pain (headache, ear pain and toothache). One patient experienced moderate
psychiatric AEs (abnormal behaviour and mood swings). Plasma concentrations of SMT
C1100 at Days 1 and 11 indicated a high degree of patient variability regardless of dose.
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Unexpectedly the SMT C1100 levels were significantly lower than similar doses adminis-
tered to healthy volunteers in an earlier clinical study. In general, individual baseline
changes of creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase
levels fell with SMT C1100 dosing.
Conclusions
SMT C1100 was well tolerated in pediatric DMD patients.
Trial Registration
ClinicalTrials.gov NCT02383511
Introduction
Duchenne muscular dystrophy (DMD) is one of the most prevalent neuromuscular disorders
and is caused by mutations in the dystrophin gene [1,2]. The lack of functional dystrophin
results in repeated cycles of muscle necrosis and regeneration leading to eventual replacement
of muscle fibers by adipose and connective tissue. Utrophin has been evaluated as a potential
replacement for dystrophin, being an autosomal homologue of dystrophin that is normally
expressed in early skeletal muscle development in the absence of dystrophin [3–6]. Towards
the end of gestation as the muscle matures, dystrophin transcription is turned on and utrophin
transcription is decreased. In mature skeletal muscle, utrophin is localized at the neuromuscu-
lar and myotendinous junctions and in regenerating myofibers.
SMT C1100 is a utrophin modulator that is being studied as a replacement for the absent
dystrophin in DMD [7]. Both utrophin mRNA and protein levels have been shown to increase
in in-vitro studies involving human cells and dosing with SMT C1100 [8]. In a dystrophic
mouse model of DMD, SMT C1100 treatment reduced muscle pathology; exercise capabilities
were improved with increasing levels of utrophin [8]. A Phase 1 study in healthy volunteers
reported that SMT C1100 was safe and well tolerated and that oral administration resulted in
higher plasma levels than those required to cause a 50% increase in levels of utrophin in cells in
vitro [9].
The current study was the first time a utrophin modulator drug had been tested in DMD
patients. The study aimed to evaluate safety and tolerability of single and multiple doses of
SMT C1100, as well as analyze potential of biomarkers of muscle damage.
Materials and Methods
The study was a multicenter, Phase 1, single and multiple ascending dose study conducted in
pediatric DMD patients. The study was initiated on 2 December 2013 (date of first informed
consent) and the final post-study observation was recorded on 8 May 2014. Four study sites
were involved, namely Great Ormond Street Hospital for Children NHS Foundation Trust,
London, UK; Alder Hey Children's NHS Foundation Trust, Liverpool, UK; Birmingham Heart-
lands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK; and Royal Man-
chester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust,
Manchester, UK. The protocol and consent form were reviewed by the Ethics Committee (EC)
and the study commenced after receipt of a Clinical Trials Authorization from the Medicines
and Healthcare products Regulatory Agency (MHRA) and EC approval: Clinical Trial Registry
No. NCT02056808. The EC that reviewed the study was NRES Committee London—West
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London & GTAC. The study was conducted in accordance with the relevant articles of the
“Declaration of Helsinki” and International Conference on Harmonization (ICH) Good Clini-
cal Practices (GCP) consolidated guidelines.
Study population
Included in the study were pediatric male patients, aged 5–11 yrs, of any ethnic origin with a
genetic diagnosis of DMD. Excluded from the study were patients who had been in a therapeu-
tic clinical trial in the previous 3 months or five times the half-life (whichever was longer);
those who had initiated or changed regimen (other than dose modifications for body weight)
of systemic corticosteroid therapy within 2 months of the trial start or had discontinued steroid
therapy within 30 days of start; known hypersensitivity to excipients of the study drug or a pre-
vious history of specific drug allergy; use of prohibited medication; need for mechanical venti-
lation; those who were non-ambulatory; patients with acute clinical illness within 4 weeks of
start; any comorbidity or medical condition determined by an investigator to compromise the
ability of the patient to undergo the study procedures; symptomatic cardiomyopathy; those
with specific abnormality in the 12-lead electrocardiogram (ECG); patients exposed to daily
passive smoking; and patients who undertook excessive exercise. Patients were selected for
screening by the Principal Investigator at each study site, where they previously had their regu-
lar clinic visits.
A parent/legal guardian was required to date and sign written consent on behalf of the
patient, according to International Conference on Harmonization (ICH) and local regulations.
This person had to understand the contents of the consent, requirements of the study and have
had an opportunity to review questions with a medically trained member of the site study
team. The patient was required to be willing to give written age appropriate assent to
participate.
Study design
The primary objective of this open label study was to determine the safety and tolerability of
single and multiple oral doses of SMT C1100 in pediatric patients with DMD. The secondary
objective was to determine the single and multiple oral dose pharmacokinetics (PK) of SMT
C1100 and its metabolites in pediatric patients with DMD. An exploratory objective was to
quantify potential systemic activity biomarkers in blood to assess: 1) variability between indi-
viduals and 2) whether multiple doses of SMT C1100 had any impact on the variability. Twelve
patients were studied in three escalating dose cohorts comprising four patients each (A–C).
Group A patients received a single 50 mg/kg dose on Day 1, followed by twice daily (bid) on
Days 2 to 10, and a final single dose on the morning of Day 11. Group B patients received a sin-
gle 100 mg/kg dose on Day 1, followed by twice daily (bid) on Days 2 to 10, and a final single
dose on the morning of Day 11. Group C patients received a single 100 mg/kg dose on Day 1,
followed by 100 mg/kg tid, with 5 to 7 hours between doses on Days 2 to 10 and a final single
dose on the morning of Day 11). The food administered during the study was not standardized.
A safety review was performed on all patients following the single dose administered on Day 1
and there was a 48 hour period between dosing of each patient. In addition, there was at least 2
weeks between each dose escalation, to allow a satisfactory review of safety, tolerability and
pharmacokinetic data. Dose escalation between groups would have been stopped or amended
if the mean steady-state maximum observed plasma concentration (Cmax) of the previous
group was> 1670 ng/mL and the mean steady-state area under the plasma concentration ver-
sus time curve (AUC) over a dosing interval (AUC0- τ) was> 17818 ng.h/mL. In addition,
dose escalation would have been stopped if clinically relevant signs or symptoms of a similar
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nature occurred in two or more patients within a group. The study design is shown in Fig 1.
Each patient participated in one 11-day treatment period only.
SMT C1100 formulation and administration
SMT C1100 was given as an aqueous microfluidized suspension within 10 minutes of consuming
food. Patients were dosed while standing and were not allowed to lie supine for 2 hours post-
morning dose, except for study procedures or if clinically indicated. Patients were not allowed
any additional fluid, with the exception of water, for 2 hours after dosing. SMT C1100 was
administered by parents when at home or by the nurse/PI when in the clinic for the assessments.
Assessment
Screening was performed within 28 days prior to first dose and patients were assessed accord-
ing to the inclusion and exclusion criteria. A physical examination was conducted as well as
clinical laboratory evaluations and a 12-lead ECG. Body weight, blood pressure, pulse rate and
body temperature were determined.
Bioanalysis
Plasma samples were prepared from the blood samples and extracted with acetonitrile. Con-
centrations of SMT C1100 were determined using a validated LC-MS/MS method (range
2–2000 ng/mL; overall method accuracy and precision 85–115% and 15%, respectively, 80–
120% and 20% at LLOQ). Quantitative analysis of dihydrodiol metabolites was performed
by LC-MS/MS. Plasma and urine samples were analyzed for the presence of metabolites using
accurate mass LC-MS on a Thermo LTQ Orbitrap mass spectrometer, equipped with a UPLC
Fig 1. Study flow chart showing amultiple ascending dose design.
doi:10.1371/journal.pone.0152840.g001
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system and online UV detection. Additional LC-MSn analyses were performed on selected
samples to elucidate the structures of the most abundant metabolites. Relative abundances of
metabolites were estimated by assuming equivalent detector response to parent SMT C1100.
Pharmacokinetic analysis
PK assessment was conducted on Day 1 at 0, 1, 2, 3, 4, 6, 9, 12 and 24 hours post-dose and on
Day 11 at 0, 1, 2, 3, 4, 6, 9, 12 and 24 hours post-dose. Blood samples (1.1 ml) were collected at
these timepoints. Urine samples were collected on Day 11 at 0–8 hours. PK parameters were
determined from the plasma concentrations of SMT C1100 using non-compartmental proce-
dures in validated software (WinNonlin Version 6.2.1 or greater, Pharsight Corporation,
Mountain View, California, USA). The PK population consisted of all patients who received at
least one dose of SMT C1100 and had evaluable data. Individual blood samples were analyzed
for plasma concentrations of SMT C1100 parent and its major metabolites–dihydrodiol
(DHD) 1 and DHD 3. Urine samples were profiled for SMT C1100 metabolites.
Fibrosis biomarkers
The following fibrosis biomarkers were evaluated in serum: P1NP (amino pro-peptide of type I
collagen); C1M (matrix metalloproteinase [MMP] generated fragment of type I collagen); and
C3M (MMP generated fragment of type III collagen). Quantification of the peptide biomarkers
was conducted by Nordic Bioscience using a validated peptide-specific enzyme-linked immu-
nosorbent assay (ELISA). Samples measured were those taken on Days 1 and 11 predose.
Safety
The safety population consisted of all patients who received at least one dose of SMT C1100.
Safety was monitored throughout the study and adverse events (AEs) and serious AEs (SAEs)
recorded. Safety was evaluated again 5 to 7 days post final dose. Clinical laboratory evaluations
were conducted in the morning of Days 7 and 12. Vital signs were monitored on Days 1, 2, 7,
11, and 12.
Statistical analysis
Data were summarized by day and, where appropriate, by assessment time for each treatment
group. Combining data across treatment groups the changes in laboratory parameters from
baseline (average of screening and pre-dose data) were estimated, along with 95% confidence
intervals, for Day 7, Day 12 and follow-up assessments. As data were analyzed on the logarithm
scale the estimated changes are in the form of ratios to baseline when back-transformed. Data
analysis was performed using SAS1 Version 9.3.
Results
All patients completed the study. Patient demographics are shown in Table 1. The mean age,
weight and BMI were similar across treatment groups. All patients were receiving a systemic
corticosteroid for DMD and most were receiving bisphosphonates. Only one patient was
receiving a cardiac medication (angiotensin converting enzyme inhibitor). Vitamin supple-
mentation was also common, with 10 patients receiving supplementation.
Safety
None of the stopping criteria for dose escalation were reached during the study. No SAEs and
no study discontinuations due to AEs were reported during the study. Treatment emergent
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AEs due to all causalities are shown in Table 2. The majority of drug-related TEAEs following
single and multiple oral doses of SMT C1100 were gastrointestinal disorders, which were mild
in severity and resolved without treatment. The most common drug-related TEAEs following a
single oral dose during the study was pale feces reported by seven patients. The majority of
these patients receiving the higher dose of SMT C1100 (three out of four subjects in both
Table 2. Treatment emergent adverse events: all causalities.
Group A Group B Group C
Overall 4 (100%) 4 (100%) 4 (100%)
Gastrointestinal disorders
Pale feces 1 3 3
Diarrhea 2 1 1
Upper abdominal pain 2 0 0
Abdominal pain 1 0 0
Constipation 1 0 0
Dyspepsia 1 0 0
Flatulence 0 1 0
Frequent bowel movements 0 1 0
Toothache 0 1 0
Skin and subcutaneous tissue disorders
Allergic dermatitis 0 1 0
Eczema 0 1 0
Rash 2 0 0
Rash erythematous 1 0 0
Psychiatric disorders
Abnormal behavior 1 0 0
Mood swings 1 0 0
Respiratory, thoracic and mediastinal disorders
Cough 0 0 1
Sneeze 0 0 1
Ear and labyrinth disorders
Ear pain 1 0 0
General disorders and administration site conditions
Increased energy 0 0 1
Nervous system disorders
Headache 1 0 0
doi:10.1371/journal.pone.0152840.t002
Table 1. Baseline patient characteristics.
Parameter Group A Group B Group C
(n = 4) (n = 4) (n = 4)
Age, mean, range, yrs 9 8 8
6–11 6–8 6–10
Time since DMD diagnosis, mean, range, yrs 4 4 4
2–5 2–6 3–5
Weight, mean, range, kg 34.0 31.6 28.5
20.5–45.9 19.1–37.0 18.7–38.2
BMI, mean, range 20.3 20.5 19.2
15.8–23.6 15.5–23.7 15.7–23.7
doi:10.1371/journal.pone.0152840.t001
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Groups B and C). At the higher dose levels (Groups B and C) the first occurrence of pale feces
reported by a patient began within 4 days of the first dose, and resolution of these TEAEs gen-
erally occurred within 3 days of the final dose. The only other drug-related TEAEs reported by
more than one patient following multiple oral doses were pain in the upper abdomen and diar-
rhea. There were two TEAEs of moderate severity reported, which were abnormal behavior
and mood swings and both occurred in one patient of Group A; both were considered as possi-
bly drug-related. Abnormal behavior and mood swings are frequently seen in patients with
DMD and maybe partially due to the lack of dystrophin in the CNS, steroid therapy or other
unknown factors. The majority of TEAEs resolved without treatment; two patients required
analgesia for pain (headache, ear pain and toothache).
All patient values were within normal limits for blood pressure; pulse rate; body tempera-
ture; 12-lead ECG data (PR interval, QRS duration, QTcB interval, morphology); clinical labo-
ratory evaluation; and physical examination.
Pharmacokinetics
Data on all 12 patients were included in the PK analysis. Plasma concentrations of SMT C1100
in individual patients in Groups A to C at Day 1 and Day 11 are shown in Fig 2 and indicate a
high degree of patient variability regardless of dose. Patient 4101 in Group B was inadvertently
administered a second dose with their evening meal which gives rise to the second elevated
peak in their PK profile on Day 11.
Individual and mean PK data following single and multiple oral doses of SMT C1100 are
shown in Tables 3 and 4, respectively. SMT C1100 was rapidly absorbed at all dose levels, with
median tmax between approximately 1 to 2 hours postdose after single doses on Day 1 and at
steady-state on Day 11. For individual patients on these days, tmax was in the range of 1 to 6
hours postdose. For AUC0-tlast (Day 1), AUC0- τ (Day 11) and Cmax (Days 1 and 11), the
between-patient variability at the 50 mg/kg bid, 100 mg/kg bid and 100 mg/kg tid dose levels
on Days 1 and 11, as assessed from the geometric CV%, was high, ranging between approxi-
mately 78% and 248%. One patient in Group B had considerably higher exposure than all
other patients investigated, with AUC0-tlast (Day 1) and AUC0- τ (Day 11) values of 2258 ng.h/
mL and 1215 ng.h/mL respectively, compared with the next highest values of 847 ng.h/mL and
411 ng/h/mL on Days 1 (AUC0-tlast) and 11 (AUC0- τ) respectively. Individual AUC0-tlast values
(excluding this patient) on Day 1 ranged from 85.9 ng.h/mL to 847 ng.h/mL. Similarly on Day
11, AUC0- τ values ranged from 28.8 ng.h/mL to 411 ng.h/mL. There was no evidence of expo-
sure increasing with dose or change in regimen.
After reaching Cmax, plasma concentrations of SMT C1100 appeared to decline in a gener-
ally biphasic manner, with resultant mean t1/2 of approximately 5 to 10 hours on Day 1, with
individual values across all doses ranging from 2.01 to 20.1 hours. On Day 11, the mean t1/2
was approximately 7 to 8 hours (individual values across all doses ranged from 2.29 to 14.9
hours). A decrease in SMT C1100 systemic exposure over the dosing period was observed with
the estimated RAobs (based on AUC0-τ) ranging from 0.352 to 0.439.
Pharmacokinetics of SMT C1100 metabolites
A total of 17 metabolites were detected in the plasma samples and 25 metabolites detected in the
urine samples analyzed. The individual profiles were generally considered comparable across the
three dose levels. The most abundant plasmametabolites were dihydrodiol 1 and dihydrodiol 3
(DHD 1 and DHD 3 respectively), with them accounting for>90% of the total drug related expo-
sure on Day 1, and approximately 70% onDay 11. In urine samples, the primary biotransformations
were hydroxylations of SMT C1100 and glucuronide conjugates of these hydroxyl metabolites.
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PLOS ONE | DOI:10.1371/journal.pone.0152840 April 7, 2016 7 / 16
Fig 2. Individual plasma concentrations of SMT C1100 for each of four patients in Groups A (black line), B (red line) and C (blue line). Group A patients
received a single 50 mg/kg dose on Day 1 and on the morning of Day 11, with 50 mg/kg bid on Days 2 to 10. Group B and Group C patients received a single
100 mg/kg dose on Day 1 and on the morning of Day 11, with 100 mg/kg bid (Group B) or 100 mg/kg tid (Group C) on Days 2 to 10.
doi:10.1371/journal.pone.0152840.g002
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Dihydrodiol Analysis
DHD1 was rapidly formed at all dose levels, with median tmax between approximately 1.5 and
2 hours postdose after single doses on Day 1, and between approximately 1.5 and 2.5 hours
postdose at steady-state on Day 11. For all individual patients on these days, tmax was in the
range of 1 to 6 hours postdose. After reaching Cmax, plasma concentrations of DHD 1 appeared
to decline in a generally biphasic manner. The mean t1/2 was approximately 6 to 8 hours on
Day 1, with individual values across all doses ranging from 4.39 to 11.6 hours. On Day 11, the
mean t1/2 was approximately 5 hours (individual values across all doses ranged from 2.91 to
6.92 hours). No accumulation of DHD 1 was observed on multiple dosing, with the estimated
RAObs (based on AUC0-τ) ranging from 0.690 at 50 mg/kg bid to 1.02 and 0.909 at 100 mg/kg
bid and tid doses, respectively.
DHD3 was more steadily formed compared with DHD 1, with median tmax between
approximately 2.5 and 4 hours postdose after single doses on Day 1, and between approxi-
mately 2 and 3 hours postdose at steady-state on Day 11. For all individual patients on these
Table 3. Individual andmean pharmacokinetics for SMT C1100 following single (Day 1) oral doses.
AUC0-1 AUC0-tlast AUC0- τ
a Cmax Cav tmax t½ CL/F Vz/F
Group A (50 mg/kg) ng.h/ml ng/mL h mL/min/kg L/kg
1101 91.2 85.9 89.5 22.1 7.46 1.00 2.01 9140 1589
1102 786 724 645 265 53.7 1.00 9.11b 1060 836
2101 246 224 186 52.6 15.5 1.03 7.66 3383 2242
2102 905 847 684 118 57.0 4.02 5.84 921 465
Mean 356 330 293 77.6 24.4 1.02c 6.15d 2340 1080
CV% 148 148 130 146 130 49.9d 148 79.1
Group B (100 mg/kg)
1103 137 132 135 71.4 11.3 1.15 2.16 12158 2271
2103 796 773 687 140 57.3 2.00 5.10 2095 925
3101 399 388 351 119 29.2 1.03 5.07 4182 1835
4101 2446 2258 1921 375 160 2.05 7.57b 681 447
Mean 500
CV% 158
Group C (100 mg/kg)
1104 1081e 668 325 134 54.2 0.98 20.1b 1542e 2687e
2104 123 117 107 48.0 17.8 1.00 2.02 13572 2370
3102 377 344 193 50.8 32.1 1.00 7.81b 4421 2991
4103 908 819 561 188 93.5 1.00 10.0b 1836 1593
Mean 462 459 248 113 41.5 1.02c 7.48d 3610 1530
CV% 146 128 81.0 78.5 105.8 77.5d 146 74.0
Geometric mean and % coefﬁcient of variation are shown, unless stated otherwise; data from Groups B and C are combined where appropriate.
AUC0-1 = area under the plasma concentration-time curve from time zero to inﬁnity; AUC0-tlast = area under the plasma concentration-time curve from
time zero up to the last quantiﬁable concentration; AUC0- τ = area under the plasma concentration-time curve over a dosing interval; Cmax = maximum
observed plasma concentration; Cav = average plasma concentration over a dosing interval; tmax = time of maximum observed plasma concentration; t½ =
apparent plasma terminal elimination half-life; CL/F = apparent total plasma clearance; Vz/F = apparent volume of distribution during the terminal phase
a the dosing interval was 12 h for bid dosing (Groups A & B) and 6 h for tid dosing (Group C)
b elimination rate constant calculated over a period of <2 half-lives
c median
d arithmetic mean and CV% presented
e extrapolated area of AUC0-1 >30%, excluded from summary statistics.
doi:10.1371/journal.pone.0152840.t003
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days, tmax was in the range of 1.98 to 8.97 hours postdose. After reaching Cmax, plasma concen-
trations of DHD 3 appeared to decline in a generally biphasic manner. The mean t1/2 was gen-
erally similar across dose and between days, ranging from approximately 4 to 5 hours, with
individual values ranging from approximately 2.7 to 7.6 hours. The exception was a mean t1/2
of approximately 23 hours for the 100 mg/kg tid dose group on Day 1, where the longer t1/2
estimates of 50.4 and 13.7 hours were calculated over a period of less than 2 half-lives and
therefore, these data should be interpreted with caution. No accumulation of DHD 3 was
observed on multiple dosing, with the estimated RAObs (based on AUC0-τ) ranging from 0.609
at 50 mg/kg bid to 0.937 and 0.954 at 100 mg/kg bid and tid doses, respectively.
In consideration of the high between-patient variability, the PK analysis of metabolites
DHD 1 and DHD 3 obtained from an exploratory assay revealed broadly similar disposition
Table 4. Individual andmean pharmacokinetics for SMT C1100 following multiple (Day 11) oral doses.
AUC0- τ
a Cmax Cav tmax t½ PTF CL/F Vz/F RAobs RL
Group A (50 mg/kg bid) ng.h/ml ng/mL h mL/min/kg L/kg
1101 33.8 10.7 2.82 1.02 2.29b NCc 24668 4895 0.38 0.37
1102 245 45.7 20.4 2.00 14.9 b 3.49 3403 4404 0.38 0.31
2101 80.1 21.4 6.68 1.00 NC 9.11 10401 NC 0.43 0.33
2102 411 48.8 34.2 6.00 6.73 4.65 2028 1182 0.60 0.45
Mean 128 26.7 10.7 1.51d 7.99e 5.29 6490 2940 0.439 0.361
CV% 159 81.8 159 6.42 e 52.4 159 93.4 22.1 17.0
Group B (100 mg/kg bid)
1103 43.9 9.24 3.66 1.00 5.20b NCc 37982 17090 0.32 0.32
2103 207 27.0 17.3 3.00 5.86 3.28 8045 4078 0.30 0.26
3101 110 20.7 9.15 2.02 12.4 b 4.42 15171 16293 0.31 0.28
4101 1215f 182f 101f 2.00 3.78f 3.11f 1372f 448f 0.63f 0.50f
Mean 187 31.1 15.6 2.01d 6.81 e 3.56 8930 4750 0.373 0.327
CV% 248 198 248 3.83 e 19.2 248 418 36.4 29.9
Group C (100 mg/kg bid)
1104 67.4 16.7 11.2 1.00 8.49 b 3.44 24733 18180 0.21 0.06g
2104 28.8 6.50 4.79 1.00 3.87 b 2.74 57931 19391 0.27 0.23
3102 93.1 18.2 15.5 1.00 8.39 b 1.05 17902 13007 0.48 0.25
4103 320 87.3 53.3 1.00 NC 3.75 5209 NC 0.57 0.35
Mean 87.2 20.4 14.5 1.00d 6.92 e 2.47 19100 16600 0.352 0.273
CV% 131 148 131 2.64 e 63.8 131 21.7 50.6 22.5
Geometric mean and % coefﬁcient of variation are shown, unless stated otherwise.
AUC0- τ = area under the plasma concentration-time curve over a dosing interval; Cmax = maximum observed plasma concentration; Cav = average
plasma concentration over a dosing interval; tmax = time of maximum observed plasma concentration; t½ = apparent plasma terminal elimination half-life;
PTF = peak to trough ﬂuctuation (Cmax / Ctrough); CL/F = apparent total plasma clearance; Vz/F = apparent volume of distribution during the terminal
phase; RAobs = observed accumulation ratio based on AUC0- τ (Day 11/Day 1); RL = ratio of linearity, based on AUC0- τ (Day 11)/ AUC0-1 (Day 1)
a the dosing interval was 12 h for bid dosing and 6 h for tid dosing
b elimination rate constant calculated over a period of <2 half-lives
c not calculated due to trough concentrations <limit of quantiﬁcation
d median
e arithmetic mean and CV%
f second dose taken in error following 9 hour sample, 24 hour concentration used as an imputation for the anomalous 12 hour concentration for derivation
of PK parameters
g extrapolated area of AUC0-1 >30%, excluded from summary statistics.
doi:10.1371/journal.pone.0152840.t004
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(tmax and t1/2) to that of the parent drug. Both metabolites were markedly more abundant than
SMT C1100 in plasma, with mean metabolite ratios appearing independent of dose. However,
as the exposure of DHD 1 and DHD 3 at 100 mg/kg bid and tid doses was similar between
Days 1 and 11, these data indicate that the increase in metabolite ratios are a reflection of a
reduction in exposure to SMT C1100 over time.
Lipid and cholate levels
There were no consistent increases or decreases observed in serum lipid biomarkers from Day
1 predose to Day 11 predose for the 11 patients assessed at both timepoints. Upon comparison
to baseline (Day 1 predose), changes ranged from -2.3 to 2.2 mmol/L for cholesterol, -1.2 to 0.9
mmol/L for triglycerides, -0.6 to 1.0 mmol/L for high-density lipoprotein (HDL) cholesterol,
-1.3 to 2.1 mmol/L for low-density lipoprotein cholesterol and -1.3 to 2.2 mmol/L for choles-
terol:HDL cholesterol ratios. Several of the serum cholate biomarkers, namely taurocholic acid,
lithocholic acid, glycolithocholic acid, tauroursodeoxycholic acid and taurolithocholic acid
were reported as below the lower limit of quantification for the majority of patients on both
Days 1 and 11 (predose). There were no consistent changes in serum cholate biomarkers
deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, chenodeoxycholic acid, glyco-
chenodeoxycholic acid, taurochenodeoxycholic acid, ursodeoxycholic acid, glycoursodeoxy-
cholic acid, cholic acid and glycocholic acid from Day 1 predose to Day 11 predose, with
approximately equal numbers of patients showing increases and decreases in these parameters.
Upon comparison to baseline (Day 1 predose), changes ranged from -1.3 to 4.2 μmol/L across
the majority of these quantifiable cholate parameters, with the greatest individual patient
changes observed in glycochenodeoxycholic acid.
Muscle damage biomarkers
Statistical significant reductions in plasma CPK, ALT and AST levels were observed with all
three enzymes compared with baseline levels during the 11 days of dosing (Fig 3). Other liver
associated markers, gamma-glutamyl transferase (GGT), ALK and ALB, showed no clinically
significant change over the same dosing period (Fig 3). Analysis of the reduction was not dose
dependent nor parent or metabolite dependent. In addition, no relationship was observed
between the three enzyme levels and SMT C1100 exposure and dose. In most patients with
evaluable samples, individual baseline changes of CPK, ALT and AST levels fell with SMT
C1100 dosing (Fig 4).
Fibrosis biomarkers
The levels of P1NP in serum ranged from 144.7 to 687.1 ng/mL (n = 12) at Day 1 and 252.7 to
1173.5 ng/mL (n = 11) at Day 11. The levels of C1M in serum ranged from 21.6 to 85.9 ng/mL
(n = 12) at Day 1 and 32.7 to 47.9 ng/mL (n = 11) at Day 11. The levels of C3M in serum ran-
ged from 10.7 to 24.2 ng/mL (n = 12) at Day 1 and 6.5 to 20.2 ng/mL (n = 11) at Day 11. The
collagen protein fragment levels varied from individual to individual and given the short dura-
tion of dosing as expected, no obvious changes in collagen protein fragment levels were associ-
ated with reduced fibrosis pre- or postdosing.
Discussion
SMT C1100 was shown to be safe and well tolerated in this first study in pediatric DMD
patients. The most common AE was change in stool color, which occurred in 7 of the 12
patients, but generally resolved within 3 days of the final study dose. Stool discoloration has
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previously been reported in the Phase 1 study of healthy volunteers at 200 and 400 mg/kg
doses of SMT C100 and was suggested to be due to unabsorbed study drug passing through the
gastrointestinal tract [9]. There were no serious AEs. Two patients required paracetemol for
pain (headache, ear pain and toothache). One patient experienced AEs of abnormal behaviour
and mood swings. Impaired intelligence and specific learning disorders have been documented
in DMD [10]. There is also an increased risk for neuro-behavioural and neuro-developmental
disorders, including autism spectrum disorders, attention-deficit hyperactivity disorder, and
obsessive-compulsive disorder in DMD [11] and the AEs experienced by these patients might
be a reflection of that although the relationship to SMT C1100 itself cannot be ruled out. No
clinically significant findings were reported for clinical laboratory evaluations, vital signs,
12-lead ECGs or physical examinations performed during the study. This is consistent with the
findings previously reported in human volunteers [9].
The PK study showed that following single and multiple oral administrations, SMT C1100
was rapidly absorbed (tmax being attained within approximately 1 to 6 hours in all patients).
SMT C1100 exhibited biphasic elimination with an apparent dose-independent terminal elimi-
nation half-life, with mean t1/2 ranging from approximately 5 to 10 hours. Drugs with such PK
properties are commonly administered every 1 to 3 half-lives, depending upon therapeutic
index and consideration of the convenience of dosing. In the current study, tid administration
did not show beneficial results over bid. Therefore, the PK information derived from this study
suggests that the optimal dosing regimen of SMT C1100 for use in further studies is likely to be
based on a bid regimen, although the effects of changes in the diet of patients and any changes
in formulation will also have to be investigated. Similar to a previous clinical study [9]
Fig 3. Plot of the average reduction from baseline (estimate, square) of the following plasmamarkers:
creatine phosphokinase (CPK), alanine aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase (ALK), gamma-glutamyl transferase (GGT), and albumen (ALB).Upper and lower
95% confidence intervals for the following time points after dosing shown: Day 7, Day 12, and follow-up (3
days after completion of dosing).
doi:10.1371/journal.pone.0152840.g003
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conducted in healthy adults, single and multiple oral dose PK of SMT C1100 in male pediatric
patients with DMD demonstrated large variability between patients. Between-patient variabil-
ity (geometric CV%) of AUC0-tlast, AUC0-τ and Cmax was high, ranging from approximately
78% to 248%. The comparison of doses and regimens was hindered by this large variability and
only having four patients per group.
In the previous Phase 1 study in healthy volunteers, a food effect of up to approximately
4-fold greater SMT C1100 exposure was observed and so patients were instructed to take drug
doses within 10 minutes of food in this study. Despite this instruction, observed exposures to
SMT C1100 were lower than anticipated; however, there was no standardization of meals con-
sumed prior to dosing and consequently it is unknown what contribution differences in food
intake or individual diet had on the extent of SMT C1100 exposure and between-patient
variability.
Comparison of the average exposure from the 10 boys who had unexpectedly low exposure
are shown in Fig 5 compared with the average of the five healthy volunteers fasted prior to sin-
gle 200 mg/kg dose of SMT C1100. These fed DMD boys show exposure levels that seem to
more closely resemble those of a fasted adult, which may be due to a low fat diet and/or related
Fig 4. Individual patient waterfall plots of gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), creatine phosphokinase (CPK),
and alanine aminotransferase (ALT) showing changes from baseline after 10 days of dosing with SMT C1100.
doi:10.1371/journal.pone.0152840.g004
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to the disease itself. SMT C1100 is currently being evaluated in a similar cohort of patients fol-
lowing a balanced diet in order to address the unexpectedly low exposure levels (see www.
clinicaltrials.gov; NCT02383511).
SMT C1100 exposure was significantly reduced following 11 days of bid dosing, with sys-
temic exposure (assessed by AUC0-τ) being approximately 56% to 65% lower on Day 11 com-
pared with Day 1. A time-dependent reduction in exposure was observed in the healthy
volunteer Phase 1 study, albeit not to the same magnitude (23% to 40% reduction) [9].
Data from in vitro and in vivo analyses has demonstrated that exposure to SMT C1100
above 0.2 μM (67 ng/ml) leads to a 50% increase in utrophin protein in the DMDmyoblast in
vitro cell assays [8]. Table 2 demonstrates that plasma levels in excess of 67 ng/ml were
achieved for a period of time on Day 1 in two patients in Group A, four patients in Group B
and two patients in Group C. After repeat dosing, one patient in Group B achieved plasma lev-
els in excess of 67 ng/ml on Day 11 for 9 hours. This patient was incorrectly administered a sec-
ond dose in the afternoon which led to the additional peak of exposure. However, with this
patient at least, it confirms the feasibility for a DMD pediatric patient dosed with 100 mg/kg
bid to achieve plasma levels of SMT C1100 above that expected to modulate utrophin. At Day
11 in a second boy in Group C, SMT C1100 plasma levels above 67 ng/ml were also achieved
for approximately 2 hours after a single dose.
A total of 17 metabolites were detected in the plasma samples and 25 metabolites detected
in the urine samples analyzed. The individual profiles were generally considered comparable
across the three dose levels. The most abundant plasma metabolites were DHD 1 and DHD 3,
accounting for> 90% of the total drug-related exposure on Day 1, and approximately 70% on
Day 11. In urine samples, the primary biotransformations were hydroxylations of SMT C1100
and glucuronide conjugates of these hydroxyl metabolites.
There were no apparent consistent changes in serum lipid and cholate biomarkers from
Day 1 predose to Day 11 predose. Serum concentrations observed for deoxycholic acid, cholic
acid and chenodeoxycholic acid were similar to the low levels reported by Tanaka et al [12] for
DMD patients compared with controls; although, the ages of the DMD patients who partici-
pated in this study were generally lower. Interpretation of the data was difficult with only one
Fig 5. Comparison of the average plasma levels of SMT C1100 from the 10 Duchenne muscular
dystrophy pediatric patients (DMD fed) who had unexpectedly low exposure to SMT C1100 compared
with the average plasma level of five healthy volunteers (HV) fasted prior to a single 200 mg/kg dose
of SMT C1100.
doi:10.1371/journal.pone.0152840.g005
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timepoint postdose and no placebo-control group. As a consequence, additional studies with
SMT C1100 will be required to make a further assessment of these biomarkers.
The observation of a decrease in serum biomarkers of muscle damage after treatment with
SMT C1100 suggested the possibility that even relatively short term dosing with SMT C1100
can lead to stabilization of the muscle membranes. In 10 of the 11 patients with evaluable sam-
ples, the level of CPK in the serum fell between baseline (average of screening and pre-dose
data) and Day 10. For AST and ALT, serum levels fell between baseline and Day 10 in 11 and
12 patients, respectively. This result is consistent with SMT C1100 treatment of mdx mice,
which demonstrated a significant fall in CPK levels after 15 days of dosing with a single 50 mg/
kg daily dose of SMT C1100 [8]. Further assessment of this phenomenon in a placebo con-
trolled study will provide further clarification. Of interest, dystrophin replacement therapies in
development that have the potential to stabilize the muscle membrane have also shown evi-
dence of reducing serum CPK levels. In the Phase 2a open label ataluren trial, CPK levels fell
significantly below baseline levels following 28 days of treatment [13] and a reduction of CPK
was also reported in the recent phase 2b drisapersen study [14].
Conclusions
Single and multiple oral doses of 50 and 100 mg/kg bid or 100 mg/kg tid SMT C1100 were
shown to be well tolerated in pediatric DMD patients, with two patients requiring analgesic
treatment for an AE. The most frequently reported TEAEs following multiple oral doses of
SMT C1100 were pale feces, which is thought to be due to the passage of unabsorbed drug.
SMT C1100 plasma exposure was lower than expected regardless of dosing regimen when com-
pared with similar doses administered to healthy volunteers in a previous clinical study. The
profile was similar to the previous healthy volunteer study when fasted suggesting that absorp-
tion is associated with fat digestion, with uptake via the lymphatic route. Reductions in serum
biomarkers predicating muscle fiber damage are promising, but a formal assessment of the
effect of SMT C1100 treatment on muscle damage biomarker levels will need to be performed
under double blind placebo controlled conditions.
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